Clinical Trials Logo
  1. Home
  2. Botulinum Toxins, Type A
  3. NCT05309564

Muscle Weakness Duration After Single Botulinum Toxin Injection in Masseter

Botulinum Toxins, Type A Clinical Trial

Official title:
Muscle Weakness Duration Post-injection of a Single Dose of Botulinum Toxin in the Masseter Muscle Bilaterally: a One-year Non-randomized Controlled Trial

Clinical Trial Summary

This study aimed to evaluate the duration of a reduced maximal voluntary bite force after a botulinum toxin intervention. Methods: In an intervention group, 25 units of Xeomin® (Merz Pharma GmbH & Co KGaA, Frankfurt am Main, Germany) botulinum neurotoxin type A were injected into the masseter muscles bilaterally (to a total of 50 units).

Clinical Trial Description

This study aimed to evaluate the duration of a reduced maximal voluntary bite force (MVBF) after a botulinum toxin intervention. Methods: In an intervention group, 25 units of Xeomin® (Merz Pharma GmbH & Co KGaA, Frankfurt am Main, Germany) botulinum neurotoxin type A were injected into the masseter muscles bilaterally (to a total of 50 units). A control group did not receive any intervention. MVBF was measured in Newtons using a strain gauge meter at the incisors and first molars. The intervention group was comprised of individuals seeking aesthetic treatment for masseter reduction (n = 20), and the control group (n = 12) comprised of volunteers. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05309564
Study type Interventional
Source Region Västerbotten
Contact
Status Completed
Phase N/A
Start date March 1, 2020
Completion date March 14, 2022
View Details
See also
  Status Clinical Trial Phase
Completed NCT04527744 - Application of Botulinum Toxin at the Yonsei Point for the Treatment of Gummy Smile N/A
Completed NCT05127018 - Higher Doses of Botulinum Toxin in the Treatment of Gummy Smile Phase 1/Phase 2
Completed NCT02135341 - Injections of Botulinum Toxin A in Treatment of Patients With Detrusor Overactivity and Impaired Contractility Phase 2
Completed NCT03508882 - Pretarsal Versus Preseptal Botulinum Toxin for Patients With Eyelid Spasm Phase 4
Completed NCT03054610 - Therapeutic Effect of Botulinum Toxin A for the Treatment of Plantar Fasciitis. Phase 1
Completed NCT00822523 - Assessment of the Effect of Botulinum Toxin in Extensor Digitorum Brevis Via Strain Gauge and Nerve Conduction Studies N/A
Completed NCT04820543 - Effects of Dose and Injection Site for Gummy Smile Treatment With Botulinum Type A Phase 4
Withdrawn NCT04580238 - Onabotulinum Toxin A (Botox) for the Treatment of Persistent Post-Stroke and Vascular Headache Phase 1
Completed NCT03385161 - Intraprostatic Injection of Botulinum Toxin A Versus Ethanol for Treatment of Patients With Benign Prostatic Hyperplasia N/A